Where the Swap Stops: Kidney Function, Medications, Taste, and Food Context
The subject here is potassium-containing lower-sodium table salt, but the decisive question is no longer only whether it lowers sodium. It is whether the intended person can safely handle the added potassium and whether the product will reach the part of the diet that supplies sodium. Understanding those two boundaries helps a reader distinguish a reasonable option for some adults from a choice that requires clinical caution or falls outside the evidence.
A lower-sodium label describes the mixture. It does not describe the user's kidney function, medicines, life stage, total diet or ability to keep using the product. The same formulation can therefore have a favorable average result in a trial and still be the wrong subject for self-directed use in another setting. That is not a contradiction in the evidence. It is a limit on what the evidence was designed to answer.
Why potassium handling changes the answer
When part of sodium chloride is replaced with potassium chloride, the body receives less sodium from that amount of salt and more potassium. The potassium side of the intervention is important because potassium may contribute to lower blood pressure. It is also the reason the recommendation cannot be reduced to “choose the package with the least sodium.” If potassium cannot be excreted effectively, it can accumulate in the blood.
A high level of potassium in the blood is called hyperkalaemia. The evidence sources identify it as a safety concern because it can disturb the heart's electrical rhythm and, in severe cases, contribute to sudden cardiac death. The concern is especially relevant to people with kidney disease or impaired renal function, because the kidneys are central to maintaining potassium balance. It also matters when medicines or supplements reduce the margin for safely handling additional potassium.
The World Health Organization therefore makes potassium handling the boundary of its conditional recommendation. It suggests potassium-containing lower-sodium table salt for adults in general populations who choose to use table salt, but excludes people with kidney impairments and people with other conditions or circumstances that might compromise potassium excretion. The examples include potassium-sparing medications and potassium supplements. The recommendation is a public-health guideline, not a clinical management guideline, so it does not tell an individual how to diagnose kidney disease, adjust medicines or treat a potassium abnormality.
This is why “low sodium” is an insufficient safety description. A person may know that a product contains less NaCl and still not know whether the added KCl is appropriate in their circumstances. The 2026 network review also calls for caution and further investigation in people with chronic or undiagnosed kidney disease, those taking potassium-sparing medicines and people with diabetes. It does not establish a universally safe formulation for these groups. Diabetes is a reason for greater uncertainty in the cited evidence, not a conclusion that every person with diabetes will be harmed.
The trial results have to be read with this selection effect in view. The WHO review reports that all of its included trials excluded people in whom increased potassium could potentially cause harm. Some also excluded people with diabetes. The 2026 review says that many trials excluded renal impairment and that the safety assessment in vulnerable populations was insufficient. A finding of little or no difference in hyperkalaemia or intervention-related adverse events among selected participants is reassuring within that population. It does not show that the same result would hold for people who were excluded or poorly represented.
This difference between “not observed” and “not possible” is crucial. Few trials reported hyperkalaemia, and the definitions used were variable or unclear.